Arvinas (ARVN) and Pfizer (PFE) said Tuesday that a phase 3 clinical trial of vepdegestrant monotherapy as an investigational treatment for advanced or metastatic breast cancer met its primary endpoint in the estrogen receptor 1-mutant population, but did not reach statistical significance in progression-free survival improvement in the intent-to-treat population.
The study is evaluating vepdegestrant versus fulvestrant in adults with estrogen receptor-positive, human epidermal growth factor receptor 2-negative advanced or metastatic breast cancer.
The companies said vepdegestrant showed a statistically significant and clinically meaningful improvement in progression-free survival compared with fulvestrant in patients whose tumors harbor ESR1 mutations, with the results exceeding the pre-specified target hazard ratio of 0.60.
The trial continues to assess overall survival as a secondary endpoint, the companies said.
Shares of Arvinas were down 43% in recent premarket activity while Pfizer stock was marginally lower.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。